Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
Emergent BioSolutions (NYSE: EBS) has secured approximately $27 million in international orders for delivery in 2025 for its medical countermeasures (MCM) portfolio. The orders focus on products addressing potential smallpox and anthrax threats, contributing to international market supply.
Joe Papa, president and CEO, emphasized Emergent's role as a trusted partner in supplying communities with protective medical countermeasures. The company plans to continue its international expansion efforts as part of its multi-year transformation plan, strengthening health preparedness globally.
Emergent specializes in developing, manufacturing, and supplying MCMs for national security and public health preparedness, enabling governments to respond effectively to emergencies and protect against potential threats.
Emergent BioSolutions (NYSE: EBS) ha ottenuto circa 27 milioni di dollari in ordini internazionali per la consegna nel 2025 per il suo portafoglio di contromisure mediche (MCM). Gli ordini si concentrano su prodotti che affrontano potenziali minacce di vaiolo e antrace, contribuendo all'approvvigionamento del mercato internazionale.
Joe Papa, presidente e CEO, ha sottolineato il ruolo di Emergent come partner affidabile nella fornitura di contromisure mediche protettive per le comunità. L'azienda prevede di continuare i suoi sforzi di espansione internazionale come parte del suo piano di trasformazione pluriennale, rafforzando la preparazione sanitaria a livello globale.
Emergent è specializzata nello sviluppo, nella produzione e nella fornitura di MCM per la sicurezza nazionale e la preparazione alla salute pubblica, consentendo ai governi di rispondere in modo efficace alle emergenze e di proteggere contro potenziali minacce.
Emergent BioSolutions (NYSE: EBS) ha asegurado aproximadamente 27 millones de dólares en pedidos internacionales para entrega en 2025 para su cartera de contramedidas médicas (MCM). Los pedidos se centran en productos que abordan amenazas potenciales de viruela y ántrax, contribuyendo al suministro del mercado internacional.
Joe Papa, presidente y CEO, enfatizó el papel de Emergent como un socio de confianza en el suministro de contramedidas médicas protectoras a las comunidades. La compañía planea continuar sus esfuerzos de expansión internacional como parte de su plan de transformación a varios años, fortaleciendo la preparación en salud a nivel global.
Emergent se especializa en el desarrollo, la fabricación y el suministro de MCM para la seguridad nacional y la preparación de salud pública, permitiendo a los gobiernos responder de manera efectiva a emergencias y protegerse contra amenazas potenciales.
Emergent BioSolutions (NYSE: EBS)는 2025년 배송을 위한 의료 대응 조치(MCM) 포트폴리오에 대해 약 2,700만 달러의 국제 주문을 확보했습니다. 이 주문은 잠재적인 천연두 및 탄저병 위협을 다루는 제품에 중점을 두어 국제 시장 공급에 기여하고 있습니다.
CEO인 Joe Papa는 Emergent가 지역 사회에 보호용 의료 대응 조치를 제공하는 신뢰할 수 있는 파트너로서의 역할을 강조했습니다. 회사는 다년간의 변혁 계획의 일환으로 국제적 확장 노력을 계속할 계획이며, 전 세계적으로 건강 준비 태세를 강화할 것입니다.
Emergent는 국가 안보 및 공공 건강 준비를 위한 MCM의 개발, 제조 및 공급을 전문으로 하여 정부가 비상 사태에 효과적으로 대응하고 잠재적인 위협으로부터 보호할 수 있도록 합니다.
Emergent BioSolutions (NYSE: EBS) a sécurisé environ 27 millions de dollars de commandes internationales pour une livraison en 2025 pour son portefeuille de contre-mesures médicales (MCM). Les commandes se concentrent sur des produits répondant à des menaces potentielles de variole et d'anthrax, contribuant à l'approvisionnement du marché international.
Joe Papa, président et PDG, a souligné le rôle d'Emergent en tant que partenaire de confiance pour fournir aux communautés des contre-mesures médicales protectrices. L'entreprise prévoit de poursuivre ses efforts d'expansion internationale dans le cadre de son plan de transformation pluriannuel, renforçant la préparation sanitaire à l'échelle mondiale.
Emergent se spécialise dans le développement, la fabrication et la fourniture de MCM pour la sécurité nationale et la préparation à la santé publique, permettant aux gouvernements de répondre efficacement aux urgences et de se protéger contre d'éventuelles menaces.
Emergent BioSolutions (NYSE: EBS) hat etwa 27 Millionen Dollar an internationalen Bestellungen für die Lieferung im Jahr 2025 für sein Portfolio an medizinischen Gegenmaßnahmen (MCM) gesichert. Die Bestellungen konzentrieren sich auf Produkte, die potenzielle Bedrohungen durch Pocken und Milzbrand ansprechen und zum internationalen Marktangebot beitragen.
Joe Papa, Präsident und CEO, betonte die Rolle von Emergent als vertrauenswürdigen Partner bei der Bereitstellung von schützenden medizinischen Gegenmaßnahmen für Gemeinschaften. Das Unternehmen plant, seine internationalen Expansionsbemühungen im Rahmen seines mehrjährigen Transformationsplans fortzusetzen und die Gesundheitsvorbereitung weltweit zu stärken.
Emergent ist auf die Entwicklung, Herstellung und Bereitstellung von MCM für nationale Sicherheit und öffentliche Gesundheitsvorbereitung spezialisiert, um Regierungen zu ermöglichen, effektiv auf Notfälle zu reagieren und sich gegen potenzielle Bedrohungen zu schützen.
- Secured $27 million in new international orders for 2025
- Expansion of international market presence
- Diversification of revenue streams through multiple MCM products
- None.
GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has recently secured approximately
“Emergent is a trusted partner to supply communities around the world with medical countermeasures that protect against serious health threats like smallpox and anthrax,” said Joe Papa, president and CEO of Emergent. “We are pleased to engage and support global partners in fulfilling their preparedness needs. As part of our multi-year transformation plan, we will continue to focus on international expansion efforts and strengthening health preparedness at home and abroad.”
Emergent specializes in developing, manufacturing, and supplying MCMs for national security and public health preparedness. These products enable governments to effectively respond to emergencies and protect the public from potential threats. The types and quantities of products that should be maintained in a stockpile will depend on the population requiring protection, the products available for meeting the threat, as well as government resources and priorities.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
What is the value of Emergent BioSolutions' (EBS) new international orders for 2025?
Which specific threats do EBS's new medical countermeasure orders address?
How does this order align with Emergent BioSolutions' (EBS) strategic plans?
When will Emergent BioSolutions (EBS) deliver these new international orders?
